Charles Schwab Investment Management Inc Albireo Pharma, Inc. Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$18.01 - $23.78 $44,340 - $58,546	2,462 Added 5.26%	49,296 $1.07 Million
Q3 2022 Nov 14, 2022	BUY	$16.32 - $26.37 $8,404 - $13,580	515 Added 1.11%	46,834 $907,000
Q2 2022 Aug 15, 2022	BUY	$18.54 - $37.29 $3,188 - $6,413	172 Added 0.37%	46,319 $920,000
Q1 2022 May 13, 2022	BUY	$23.94 - $33.74 $8,977 - $12,652	375 Added 0.82%	46,147 $1.38 Million
Q4 2021 Feb 11, 2022	BUY	$21.19 - $31.29 $28,776 - $42,491	1,358 Added 3.06%	45,772 $1.07 Million
Q3 2021 Nov 16, 2021	BUY	$27.36 - $35.98 $52,257 - $68,721	1,910 Added 4.49%	44,414 $1.39 Million
Q2 2021 Aug 16, 2021	SELL	$28.9 - $36.87 $9,739 - $12,425	-337 Reduced 0.79%	42,504 $1.5 Million
Q1 2021 May 17, 2021	BUY	$32.03 - $42.85 $25,047 - $33,508	782 Added 1.86%	42,841 $1.51 Million
Q4 2020 Feb 16, 2021	BUY	$31.56 - $42.16 $286,470 - $382,686	9,077 Added 27.52%	42,059 $1.58 Million
Q3 2020 Nov 13, 2020	SELL	$23.19 - $41.61 $31,236 - $56,048	-1,347 Reduced 3.92%	32,982 $1.1 Million
Q2 2020 Aug 14, 2020	BUY	$14.82 - $29.92 $23,356 - $47,153	1,576 Added 4.81%	34,329 $910,000
Q1 2020 May 15, 2020	BUY	$11.67 - $27.23 $49,259 - $114,937	4,221 Added 14.79%	32,753 $537,000
Q4 2019 Feb 07, 2020	BUY	$16.92 - $28.96 $60,049 - $102,779	3,549 Added 14.21%	28,532 $726,000
Q3 2019 Nov 08, 2019	BUY	$20.0 - $31.88 $28,140 - $44,855	1,407 Added 5.97%	24,983 $500,000
Q2 2019 Aug 09, 2019	BUY	$30.67 - $37.86 $96,181 - $118,728	3,136 Added 15.34%	23,576 $761,000
Q1 2019 May 14, 2019	BUY	$22.22 - $32.21 $29,797 - $43,193	1,341 Added 7.02%	20,440 $659,000
Q2 2018 Aug 08, 2018	BUY	$28.9 - $37.31 $551,961 - $712,583	19,099 New	19,099 $679,000

Others Institutions Holding ALBO

# of Institutions

Shares Held

865

Call Options Held

Put Options Held

View Full List

About ALBIREO PHARMA, INC.

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

More about ALBO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account